PUBLISHER: The Business Research Company | PRODUCT CODE: 1760580
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760580
Iron deficiency anemia treatment encompasses the medical strategies and interventions designed to correct iron deficiency in the body. These treatments aim to replenish iron levels through iron supplements, dietary changes, or intravenous iron, addressing the underlying cause of the deficiency and relieving associated symptoms.
The main types of iron deficiency anemia treatment include medications, blood transfusions, and other therapies. Medications refer to drugs or substances used to treat, prevent, or manage conditions including iron deficiency anemia. These include various types of iron supplements such as ferrous sulfate, ferrous gluconate, ferrous fumarate, ferric hydroxide, sodium ferric gluconate, and iron carbohydrates. These treatments are used across different therapy areas such as inflammatory bowel disease, renal disorders, obstetrics and gynecology, congestive heart failure, oncology, and more. The treatments can be administered orally or via injection and are utilized in various settings, including hospitals, clinics, home care environments, and pharmacies.
The iron deficiency anemia treatment market research report is one of a series of new reports from The Business Research Company that provides iron deficiency anemia treatment market statistics, including iron deficiency anemia treatment industry global market size, regional shares, competitors with a iron deficiency anemia treatment market share, iron deficiency anemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia treatment industry. This iron deficiency anemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The iron deficiency anemia treatment market size has grown rapidly in recent years. It will grow from $7.85 billion in 2024 to $8.89 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth during the historic period can be attributed to several factors, including the expansion of awareness programs and initiatives, the aging baby boomer population, increasing nutritional deficiencies, a rise in anemia cases worldwide, and the growing number of women of reproductive age.
The iron deficiency anemia treatment market size is expected to see rapid growth in the next few years. It will grow to $14.54 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The projected growth in the forecast period can be attributed to several factors, including increased investments in research and development, rising risks associated with pregnancy, growing nutritional deficits, heightened healthcare awareness, and the continued prevalence of iron deficiency anemia. Key trends to watch in the forecast period include the development of wearable hemoglobin monitors, the use of patient chatbots for support, the introduction of iron absorption enhancers, the expansion of remote monitoring platforms, and advancements in neurocognitive monitoring.
The growing prevalence of chronic kidney disease (CKD) is expected to drive the expansion of the iron deficiency anemia treatment market. CKD involves the gradual decline of kidney function over time, and its rise can be linked to increasing diabetes rates. High blood sugar levels over extended periods can damage the kidneys' blood vessels, impairing their ability to filter waste. Iron deficiency anemia treatment can help improve oxygen delivery to tissues, reduce fatigue, and enhance quality of life. Additionally, it may aid kidney function by addressing anemia, which is often caused by reduced erythropoietin production in CKD. A report published by AstraZeneca in April 2024 forecasts that by 2032, chronic kidney disease will affect up to 16.5 percent of the population in eight countries including the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia, with advanced stage cases expected to rise by up to 59.3 percent. This growing prevalence of CKD is fueling the demand for iron deficiency anemia treatments.
Leading companies in the iron deficiency anemia treatment market are focusing on the development of next-generation solutions, such as iron injections, to improve treatment effectiveness, safety, and patient convenience. Iron injection refers to a new or significantly enhanced injectable iron therapy, marking a significant advancement in the treatment of iron deficiency and iron deficiency anemia. For example, in March 2024, Cadila Pharmaceuticals, an India-based company, introduced Redshot FCM, an intravenous iron therapy that uses ferric carboxymaltose to treat iron deficiency anemia (IDA). This therapy offers several key benefits, including an advanced ferric carboxymaltose formulation for fast iron replenishment, low risk of anaphylaxis, high-dose single-infusion administration for quick correction, and applicability for both pediatric (ages 1 and above) and adult patients. It helps accelerate hemoglobin recovery and is particularly beneficial for high-risk groups, such as pregnant women and cancer patients, with superior tolerability.
In August 2022, CSL Limited, an Australia-based biotechnology company specializing in iron deficiency injectables, acquired Vifor Pharma for an undisclosed amount. This acquisition strengthens CSL's commitment to patient care and enhances its capacity to offer innovative treatments. Vifor Pharma is a Switzerland-based provider of intravenous iron therapies for treating iron deficiency anemia.
Major players in the iron deficiency anemia treatment market are Sanofi SA, Fresenius SE & Co. KGaA, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories, Pharmascience Inc., American Regent Inc., PharmaNutra S.p.A., Rockwell Medical Inc., Keryx Biopharmaceuticals Inc., Akebia Therapeutics Inc., Pharmacosmos A/S, Pieris Pharmaceuticals Inc., AdvaCare Pharma USA LLC, Apotex Inc., and Shield Therapeutics plc.
North America was the largest region in the iron deficiency anemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron deficiency anemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the iron deficiency anemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The iron deficiency anemia treatment market consists of revenues earned by entities by providing services such as dietary counseling, monitoring and follow-up care, customized treatment plans, and management of side effects. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia treatment market also includes sales of iron-fortified foods, iron infusion kits, liquid iron supplements, and iron-rich multivitamins. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Iron Deficiency Anemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on iron deficiency anemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for iron deficiency anemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iron deficiency anemia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.